Firering Strategic Minerals: From explorer to producer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,340.00
Bid: 12,360.00
Ask: 12,362.00
Change: -76.00 (-0.61%)
Spread: 2.00 (0.016%)
Open: 12,234.00
High: 12,370.00
Low: 12,164.00
Prev. Close: 12,416.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET MIDDAY: Hopes of rate peak, China turnaround lift stocks

Mon, 04th Sep 2023 12:13

(Alliance News) - Stock prices in London were higher at midday on Monday, with market mood buoyed by news of stimulus measures in China and increasing optimism for the future of interest rates across the Atlantic.

The FTSE 100 index was up 29.50 points, or 0.4%, at 7,494.18. The FTSE 250 was up 81.75 points, or 0.4%, at 18,618.51, and the AIM All-Share was up 0.87 of a point, or 0.1%, at 742.30.

The Cboe UK 100 was up 0.4% at 746.17, the Cboe UK 250 was up 0.6% at 16,283.69, and the Cboe Small Companies was up 0.4% at 13,061.71.

Beijing on Monday reduced borrowing requirements for homebuyers and encouraged lenders to cut interest rates on existing in a bid to shore up its embattled real estate sector. The news revived hopes that the Chinese economy may soon turn a corner.

"The [Chinese] property sector has been in the eye of the recent economic storm, but investors are coming to the conclusion that the cumulative effects of recent moves by the authorities may actually begin to move the dial," said Richard Hunter, head of markets at interactive investor.

News that battered developer Country Garden had won approval from creditors to extend a deadline for a key bond repayment also provided some much-needed relief from worries over the Chinese property sector on Monday, further bolstering market sentiment.

August's US jobs report, released on Friday, also remained a key driver of sentiment on Monday as it fuelled hopes the US Federal Reserve may make no change to rates when it meets later this month.

According to the US Bureau of Labor Statistics, total non-farm payroll employment increased by 187,000 in August, picking up from a revised rise of 157,000 in July. July's figure was revised down by 30,000 from 187,000.

August's figure came in stronger than expectations, with the market expecting 170,000 jobs to be added last month according to FXStreet-cited consensus.

KCM Trade's Tim Waterer said that the Federal Open Market Committee will be "reasonably happy" with the figures as the push higher in the unemployment rate indicates a cooling labour market which "at the very least" will help buy the US central bank some time to keep interest rates steady this month.

Currently, markets see a 93% chance of interest rates standing pat at the Federal's Reserve next meeting, according to the CME FedWatch Tool. Just one week ago, markets saw a 78% chance of this outcome.

In recent weeks, a slew of softer economic data has painted a picture of a slowing US economy, fuelling hopes that interest rates in the world's largest economy have peaked.

"It remains to be seen whether this risk appetite is sustained, but if the news from the two global economic superpowers continues to trend in the right direction, the premier index [in London] is likely to receive a knock-on benefit given the importance of overseas earnings to many of its constituents," said ii's Richard Hunter.

In London, AstraZeneca rose 0.5% as it announced that its drug Calquence is now approved in China for treatment of chronic lymphocytic leukaemia or small lymphocytic lymphoma in adult patients who have received at least one prior therapy.

Calquence already is approved for treatment of CLL and SLL in the US and Japan and is approved for CLL in the EU.

In the FTSE 250, Wizz Air added 2.1% as the budget airline reported its passenger numbers in August rose 24% year-on-year to 6.1 million, while load factor improved to 94% from 91%.

Wizz's Dublin-based counterpart, Ryanair, said passenger numbers rose 11% annually to 18.9 million in August, as load factor rose to 94% from 89%.

It also revealed around 63,000 of its passengers saw their flights cancelled during last week's air traffic control failure which caused widespread disruption across the industry and left thousands of passengers stranded overseas.

The Irish carrier said more than 350 of its flights were cancelled on August 28 and 29 due to the UK air traffic control issue.

Elsewhere in London, Capricorn Energy climbed 3.3% as the Edinburgh-based oil and gas explorer benefited from elevated oil prices.

Brent oil was quoted at USD88.67 a barrel at midday in London on Monday, up from USD88.00 at the London equities close on Friday.

The commodity has been boosted by the prospect of stronger demand from China and the US, as well as tighter supply from major oil-producing nations such as Saudi Arabia.

Gold was quoted at USD1,940.67 an ounce against USD1,938.09, meanwhile.

On AIM, Advanced Medical Solutions plunged 24% after the surgical dressings company lowered its full-year outlook due to uncertainty over royalty income from its patent licensing agreement with Organogensis.

"Given that Organogenesis has withdrawn its own guidance and that we have no control of, and minimal insight into its sales, we are unable to quantify the financial impact on AMS at this stage," the company explained.

As a result, AMS removed this royalty in its entirety from its fourth quarter guidance onwards, expecting a GBP2 million hit to adjusted pretax profit for 2023 from lower royalty revenue.

In European equities on Monday, the CAC 40 in Paris and the DAX 40 in Frankfurt were both 0.5% higher.

The pound was quoted at USD1.2635 at midday on Monday in London, up from USD1.2604 at the London equities close on Friday. The euro stood at USD1.0804, higher against USD1.0792. Against the yen, the dollar was trading at JPY146.35, higher compared to JPY146.21.

By Heather Rydings, Alliance News senior economics reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
18 Jun 2024 09:33

TOP NEWS: AstraZeneca disappointed by breast cancer drug trial results

(Alliance News) - AstraZeneca PLC on Tuesday said findings from a breast cancer drug trial showed that Truqap did not meet its primary endpoints.

Read more
18 Jun 2024 07:51

LONDON BRIEFING: Ashtead profit declines; Whitbread sales rise

(Alliance News) - London's FTSE 100 is called to open higher on Tuesday, taking confidence from a decent showing for US equities overnight, with inflation data and central bank decisions the key plot points as the week progresses.

Read more
18 Jun 2024 07:17

AstraZeneca trial fails to treat 'challenging' breast cancer

(Sharecast News) - AstraZeneca announced on Tuesday that the phase three 'CAPItello-290' trial for 'Truqap', or capivasertib, in combination with paclitaxel did not achieve its primary endpoints.

Read more
17 Jun 2024 09:09

TOP NEWS: Astra's Imfinzi plus chemo approved for cancer form in US

(Alliance News) - AstraZeneca PLC on Monday said it secured a new US approval for cancer treatment Imfinzi, also known as durvalumab, hailing an "important new option" for patients.

Read more
17 Jun 2024 07:48

LONDON BRIEFING: Astra gets US drug approval; Ascential trades in line

(Alliance News) - London's FTSE 100 is called to open solidly higher on Monday, recovering some poise after a tricky week, with eyes turning to the Bank of England.

Read more
17 Jun 2024 07:23

IN BRIEF: AstraZeneca gets positive cancer test results for Calquence

AstraZeneca PLC - Cambridge, England-based pharmaceutical maker - Reports promising test results for one of its cancer therapies. The Echo phase III trial shows that Calquence, when used in combination with bendamustine and rituximab, demonstrates a clinically meaningful improvement in progression-free survival in patients with untreated mantle cell lymphoma. Compared to standard-of-care chemoimmunotherapy, the combination with Calquence, whose generic name is acalabrutinib, shows a 27% reduced risk of disease progression or death. Mantle cell lymphoma is rare and typically aggressive form of non-Hodgkin lymphoma, Astra explains.

Read more
17 Jun 2024 07:15

AstraZeneca's Imfinzi gets US approval for endometrial cancer patients

(Sharecast News) - AstraZeneca said its Imfinzi cancer treatment had been approved in the US as treatment for adult patients with primary advanced or recurrent endometrial cancer.

Read more
12 Jun 2024 20:56

AstraZeneca's Farxiga approved to treat paediatric type-2 diabetes

(Alliance News) - AstraZeneca PLC on Wednesday said its Farxiga treatment has been approved in the US to treat some diabetes sufferers.

Read more
10 Jun 2024 09:10

LONDON BROKER RATINGS: JPMorgan cuts Aviva but lifts M&G

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and on Friday:

Read more
10 Jun 2024 08:30

TOP NEWS: Astra's Tagrisso gets US priority review for lung cancer

(Alliance News) - AstraZeneca PLC on Monday celebrated a breakthrough therapy designation for its cancer drug Tagrisso, aimed at treating a form of non-small cell lung cancer.

Read more
10 Jun 2024 07:37

LONDON BRIEFING: FTSE called down amid political uncertainty in EU

(Alliance News) - Stocks in London are called to open lower on Monday, setting off the week on the backfoot, with eyes on the US Federal Reserve's latest interest rate decision.

Read more
10 Jun 2024 06:25

London pre-open: Stocks set for lower start after EU elections

(Sharecast News) - Stocks in London look primed for a lower start as investors digest the gains made by far right parties in Austria, Germany, but above all France, at the European Union elections that were held at the weekend.

Read more
5 Jun 2024 09:52

LONDON BROKER RATINGS: Berenberg raises Taylor Wimpey to 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

Read more
5 Jun 2024 09:27

AstraZeneca completes USD2.4 billion Fusion Pharmaceuticals purchase

(Alliance News) - AstraZeneca PLC on Wednesday said it successfully completed the acquisition of Boston, Massachusetts-based Fusion Pharmaceuticals Inc.

Read more
3 Jun 2024 08:59

AstraZeneca cancer treatment Tagrisso recommended for approval in EU

(Alliance News) - AstraZeneca PLC said that, following further positive findings in clinical trial, Tagrisso has been recommended for use in the European Union.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.